公开(公告)号：US07943589B2

公开(公告)日：2011-05-17

申请号：US11916334

申请日：2006-06-05

Applicant: Judy Lieberman ,  Deborah Palliser ,  David Knipe

Inventor： Judy Lieberman ,  Deborah Palliser ,  David Knipe

IPC: A61K31/70 ,  C07H21/04 ,  C07H21/02 ,  C12Q1/68

CPC classification number: C12N15/1133 ,  A61K48/00 ,  C12N15/1131 ,  C12N2310/14

Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

Abstract translation: 本发明提供包含至少一种siRNA的杀微生物组合物。 siRNA是由一个或两个分子制成的RNA双链体。 siRNA的一部分与病毒的必需基因中的靶序列相同。 病毒可以是疱疹病毒，例如HSV-1或HSV-2。 优选地，疱疹病毒是HSV-2。 杀微生物组合物还包含药学上可接受的载体。 本发明还包括通过施用杀微生物剂组合物预防和治疗病毒感染的方法。 优选地，所述杀微生物组合物经粘膜给药。

公开(公告)号：US08895524B2

公开(公告)日：2014-11-25

申请号：US12736025

申请日：2009-03-03

Applicant: Bryan R. Cullen ,  Jennifer Lin Umbach ,  Donald M. Coen ,  Martha F. Kramer ,  Igor Jurak ,  David Knipe

Inventor： Bryan R. Cullen ,  Jennifer Lin Umbach ,  Donald M. Coen ,  Martha F. Kramer ,  Igor Jurak ,  David Knipe

IPC: A61K31/70 ,  C07H21/02 ,  C07H21/04 ,  C12N15/113 ,  A61K31/7105 ,  C12Q1/68 ,  C12N15/11

CPC classification number: C12N15/1133 ,  A61K31/7105 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/113 ,  C12N2310/141

Abstract: The present invention relates, in general, to micro RN As and, in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs and to methods of treatment based on the use of such agents.

Abstract translation: 本发明一般涉及微型RNAs，特别涉及由单纯疱疹病毒1型（HSV-1）或单纯疱疹病毒2型（HSV-2）表达的病毒微小RNA对抑制这种微小RNA的试剂和 基于使用这种药剂的治疗方法。

公开(公告)号：US20100008944A1

公开(公告)日：2010-01-14

申请号：US11989687

申请日：2006-07-26

Applicant: David Knipe ,  Timothy Dudek

Inventor： David Knipe ,  Timothy Dudek

IPC: A61K39/245 ,  C12N7/01 ,  C12N5/10 ,  C07H21/00 ,  C12N15/63 ,  A61P31/12

CPC classification number: C12N7/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5254 ,  A61K2039/541 ,  C12N2710/16634 ,  C12N2710/16661

Abstract: The invention generally provides therapeutic and prophylactic compositions that include a replication defective mutant HSV-2 virus having a mutation in a viral host shut-off protein, a herpes simplex virus having a mutation in a viral host shut-off protein and two additional mutations that render the virus replication defective, and related methods.

Abstract translation: 本发明通常提供治疗和预防组合物，其包括在病毒宿主截止蛋白中具有突变的复制缺陷突变型HSV-2病毒，在病毒宿主切断蛋白中具有突变的单纯疱疹病毒和两种另外的突变， 使病毒复制有缺陷及相关方法。

公开(公告)号：US20120087973A1

公开(公告)日：2012-04-12

申请号：US13069589

申请日：2011-03-23

Applicant: Judy Lieberman ,  Deborah Palliser ,  David Knipe

Inventor： Judy Lieberman ,  Deborah Palliser ,  David Knipe

IPC: A61K31/7105 ,  C12N5/071 ,  A61P31/14 ,  A61P31/12 ,  A61P31/22 ,  A61P31/20 ,  C12N5/00 ,  A61K9/127

CPC classification number: C12N15/1133 ,  A61K48/00 ,  C12N15/1131 ,  C12N2310/14

Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

Abstract translation: 本发明提供包含至少一种siRNA的杀微生物组合物。 siRNA是由一个或两个分子制成的RNA双链体。 siRNA的一部分与病毒的必需基因中的靶序列相同。 病毒可以是疱疹病毒，例如HSV-1或HSV-2。 优选地，疱疹病毒是HSV-2。 杀微生物组合物还包含药学上可接受的载体。 本发明还包括通过施用杀微生物剂组合物预防和治疗病毒感染的方法。 优选地，所述杀微生物组合物经粘膜给药。

公开(公告)号：US20110118332A1

公开(公告)日：2011-05-19

申请号：US12736025

申请日：2009-03-03

Applicant: Bryan R. Cullen ,  Jennifer Lin Umbach ,  Donald M. Coen ,  Martha F. Kramer ,  Igor Jurak ,  David Knipe

Inventor： Bryan R. Cullen ,  Jennifer Lin Umbach ,  Donald M. Coen ,  Martha F. Kramer ,  Igor Jurak ,  David Knipe

IPC: A61K31/7088 ,  C07H21/02 ,  C07H21/00 ,  C12N15/63 ,  C12Q1/68 ,  A61P31/22

CPC classification number: C12N15/1133 ,  A61K31/7105 ,  C12N15/111 ,  C12N2310/11 ,  C12N2310/111 ,  C12N2310/113 ,  C12N2310/141

Abstract: The present invention relates, in general, to micro RN As and. in particular, to viral microRNAs expressed by Herpes Simplex Vims 1 (HSV-1) or Herpes Simplex Virus 2 (HSV-2), to agents that inhibit such microRNAs and to methods of treatment based on the use of such agents.

Abstract translation: 本发明一般涉及微RN As和。 特别是针对由单纯疱疹病毒1（HSV-1）或单纯疱疹病毒2（HSV-2）表达的病毒微小RNA对抑制这些微小RNA的药物和基于使用这些药物的治疗方法。

公开(公告)号：US20090022783A1

公开(公告)日：2009-01-22

申请号：US11916334

申请日：2006-06-05

Applicant: Judy Lieberman ,  Deborah Palliser ,  David Knipe

Inventor： Judy Lieberman ,  Deborah Palliser ,  David Knipe

IPC: A61K9/127 ,  A61K31/7105 ,  A61P31/00 ,  C12N5/06

CPC classification number: C12N15/1133 ,  A61K48/00 ,  C12N15/1131 ,  C12N2310/14

Abstract: The invention provides a microbicidal composition comprising at least one siRNA. The siRNA is an RNA duplex made of one or two molecules. A portion of the siRNA is identical to a target sequence in an essential gene of a virus. The virus may be a herpesvirus, for example, HSV-1 or HSV-2. Preferably, the herpesvirus is HSV-2. The microbicidal composition further comprises a pharmaceutically acceptable carrier. Also included in the invention are methods to prevent and treat viral infections by administration of the microbicidal composition. Preferably, the microbicidal composition is administered transmucosally.

Abstract translation: 本发明提供包含至少一种siRNA的杀微生物组合物。 siRNA是由一个或两个分子制成的RNA双链体。 siRNA的一部分与病毒的必需基因中的靶序列相同。 病毒可以是疱疹病毒，例如HSV-1或HSV-2。 优选地，疱疹病毒是HSV-2。 杀微生物组合物还包含药学上可接受的载体。 本发明还包括通过施用杀微生物剂组合物预防和治疗病毒感染的方法。 优选地，所述杀微生物组合物经粘膜给药。

公开(公告)号：US07223411B1

公开(公告)日：2007-05-29

申请号：US08278601

申请日：1994-07-21

Applicant: David Knipe ,  Robert Finberg ,  George Siber

Inventor： David Knipe ,  Robert Finberg ,  George Siber

IPC: A61K39/245

CPC classification number: C12N7/00 ,  A61K39/00 ,  A61K39/12 ,  A61K39/245 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/55566 ,  A61K2039/57 ,  C07K14/005 ,  C07K2319/00 ,  C12N2710/16622 ,  C12N2710/16634 ,  C12N2710/16661

Abstract: A herpesvirus vaccine comprising a mutated herpesvirus suspended in a pharmaceutically acceptable carrier. The mutated herpesvirus is capable of infecting cells of the mammal to be vaccinated, but incapable of completing a replicative cycle, and it is capable of eliciting a protective immune response in that mammal. The mutated herpesvirus is also capable of treating immunomodulatory or immunoregulatory diseases. The mutation occurs in at least one gene encoding a protein essential for replication of the virus, so that the mutation renders the virus replication defective.

Abstract translation: 一种疱疹病毒疫苗，其包含悬浮在药学上可接受的载体中的突变疱疹病毒。 突变的疱疹病毒能够感染待接种的哺乳动物的细胞，但不能完成复制循环，并且能够在该哺乳动物中引发保护性免疫应答。 突变的疱疹病毒也能够治疗免疫调节或免疫调节疾病。 该突变发生在编码病毒复制必需蛋白质的至少一个基因中，从而导致病毒复制有缺陷。